Literature DB >> 2930999

Plasminogen activators, tissue degradation, and cancer.

K Danø, P A Andreasen, J Grøndahl-Hansen, P Kristensen, L S Nielsen, L Skriver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2930999     DOI： 10.1016/s0065-230x(08)60028-7

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  491 in total

1.  Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.

Authors:  A Gandorfer; E Putz; U Welge-Lüssen; M Grüterich; M Ulbig; A Kampik
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

2.  Isolation and characterization of cell lines with reduced urokinase binding.

Authors:  H K Lau; J M Teitel; M Kim
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.

Authors:  R P Czekay; T A Kuemmel; R A Orlando; M G Farquhar
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 4.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

5.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

6.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

7.  Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge.

Authors:  Margaret R Gyetko; Sudha Sud; Stephen W Chensue
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Testosterone upregulation of tissue type plasminogen activator expression in Sertoli cells : tPA expression in Sertoli cells.

Authors:  Jian Guo; Yu-Qiang Shi; Wei Yang; Yin-Chuan Li; Zhao-Yuan Hu; Yi-Xun Liu
Journal:  Endocrine       Date:  2007-10-09       Impact factor: 3.633

9.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

10.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.